The University of Oxford has become the first UK academic institution to receive support from the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) scheme for its vaccine targeting the deadly Nipah virus.
Lauren Matelski, Jeremy MacMahon, and Pamela J. Lein from the University of California, Davis, weigh the risks associated with COVID-19 vaccines versus the benefits.
Cecilia Van Cauwenberghe from Frost & Sullivan’s TechVision Group, offers preliminary context about the impact of the COVID-19 pandemic in most African countries, starting with lessons to be learned from previous outbreaks.
Luke S. P. Moore, Infectious Diseases Physician and Clinical Microbiologist on behalf of the Healthcare Infection Society, directs our thoughts to optimising our control of infections and looks forward to the post-pandemic period.
Dr Quinton Fivelman, PhD, Chief Scientific Officer at London Medical Laboratory, reveals that antibody levels for the double-jabbed are now waning. He asks was the UK Government unwise to relax most COVID precautions in July?.
Five new COVID-19 research projects will study the durability of vaccine responses, low responses linked with health conditions and the effect of booster shots.
Pregnant individuals who contract COVID-19 face a higher risk of having a preterm birth, according to researchers at The University of California, San Francisco (UCSF).
Physicians at University of California San Diego School of Medicine describe the first known case of a young, healthy adult who suffered brain inflammation after mild COVID-19 infection.
According to a new study, fenofibrate, a drug used to treat abnormal levels of fatty substances in the blood, could reduce COVID-19 infection by up to 70%.
The Joint Committee on Vaccination and Immunisation (JCVI) has recommended that all 16 and 17-year-olds should receive their first dose of the Pfizer-BioNTech vaccine.
